KAEF Stock Overview
Engages in the manufacturing and sale of pharmaceutical products in Indonesia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PT Kimia Farma Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp600.00 |
| 52 Week High | Rp1,680.00 |
| 52 Week Low | Rp535.00 |
| Beta | 0.48 |
| 1 Month Change | -1.64% |
| 3 Month Change | -21.57% |
| 1 Year Change | -60.66% |
| 3 Year Change | -75.51% |
| 5 Year Change | -52.00% |
| Change since IPO | 185.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| KAEF | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | -0.8% | -0.3% | -1.0% |
| 1Y | -60.7% | -17.5% | 3.6% |
Return vs Industry: KAEF underperformed the ID Pharmaceuticals industry which returned -20.8% over the past year.
Return vs Market: KAEF underperformed the ID Market which returned 4.1% over the past year.
Price Volatility
| KAEF volatility | |
|---|---|
| KAEF Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in ID Market | 12.9% |
| 10% least volatile stocks in ID Market | 2.4% |
Stable Share Price: KAEF has not had significant price volatility in the past 3 months compared to the ID market.
Volatility Over Time: KAEF's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1817 | 10,712 | David Utama | kimiafarma.co.id |
PT Kimia Farma Tbk engages in the manufacturing and sale of pharmaceutical products in Indonesia. It also provides generic, ethical, license and narcotic medicines, over the counter medicines, raw materials, medicines, medical devices, and cosmetic products, as well as rapid test diagnostic tools. In addition, the company is involved manufacturing and marketing of pharmaceutical raw materials and active pharmaceutical ingredients; health foods and effervescent tablets; quinine salt and related derivatives; and castor oil and edible oil.
PT Kimia Farma Tbk Fundamentals Summary
| KAEF fundamental statistics | |
|---|---|
| Market cap | Rp3.34t |
| Earnings (TTM) | -Rp1.71t |
| Revenue (TTM) | Rp10.11t |
0.3x
P/S Ratio-2.0x
P/E RatioIs KAEF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KAEF income statement (TTM) | |
|---|---|
| Revenue | Rp10.11t |
| Cost of Revenue | Rp7.82t |
| Gross Profit | Rp2.30t |
| Other Expenses | Rp4.01t |
| Earnings | -Rp1.71t |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -307.30 |
| Gross Margin | 22.69% |
| Net Profit Margin | -16.91% |
| Debt/Equity Ratio | 133.5% |
How did KAEF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 11:44 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PT Kimia Farma Tbk is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alvin Gunawan | CGS International |
| Janni Asman | Maybank Research Pte. Ltd. |
| Michael Setjoadi | PT Bahana Securities |